Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials

By afschroeder • July 4, 2026

Stein Gold L, Armstrong AW, Soung J, Vender RB, González Cantero Á, Hoffmann M, Guenthner ST, Hong HC, Murrell DF, Song EJ, Kircik L, Augustin M, Sauder M, Gerdes S, Reyes-Servin O, Edem BE, Campbell J, Cresswell K, Kephart L, Li S, Yang YW, Bissonnette R. Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials. Br J Dermatol. 2026 Jul 3:ljag264. doi: 10.1093/bjd/ljag264. Epub ahead of print. PMID: 42397072.

Tags: Dermatology, Publications

Unraveling the autoimmune architecture of pemphigus: from B-cell depletion to network-based immune engineering

Shafiei-Jahani P, Li X, Akbari A, Vera A, Haniff E, Carlisle R, Akbari O, Holland V. Unraveling the autoimmune architecture of pemphigus: from B-cell depletion[...]

Cerebriform Ridges on the Scalp Signaling a Tumor in the Brain

Park A, Kenney S, Kellogg C, Castillo JR, Bergheim T. Cerebriform Ridges on the Scalp Signaling a Tumor in the Brain. Perm J. 2026 Jul[...]

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial

Mease PJ, Chandran V, Armstrong AW, Blanco R, Ogdie A, Siegel EL, Gottlieb AB, Zeng X, Thaçi D, Kishimoto M, Schulze-Koops H, Kivitz A, Dokoupilová[...]